KFAS
AXSM icon

Keating Financial Advisory Services’s Axsome Therapeutics AXSM Stock Holding History

Keating Financial Advisory Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9K Sell
88
-8
-8% -$1.38K ﹤0.01% 1001
2025
Q4 		$17.5K Buy
+96
New +$13.4K ﹤0.01% 934

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Keating Financial Advisory Services's AXSM Position: Q1 2026 in Review

Keating Financial Advisory Services reduced its Axsome Therapeutics (AXSM) stake by 8.3% in Q1 2026, selling an estimated $1.38K and leaving 88 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Keating Financial Advisory Services first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $17.5K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Keating Financial Advisory Services held 88 shares of Axsome Therapeutics worth $14.9K as of Q1 2026.
  • Keating Financial Advisory Services sold 8 Axsome Therapeutics shares in Q1 2026, an estimated $1.38K.
  • Axsome Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #1001 holding.
  • Keating Financial Advisory Services first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Axsome Therapeutics position peaked at $17.5K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.